Allan Radaic

Dr. Allan Radaic

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2020 in Journal of Controlled Release
Verified
Journal Article
Closed access
ARAllan Radaic
Allan Radaic
MJMarcelo Bispo de Jesus
Marcelo Bispo de Jesus
YKYvonne L. Kapila
Yvonne L. Kapila

18 December 2019 in Periodontology 2000
Verified
Journal Article
Closed access
PDF file
TNTrang Nguyen
Trang Nguyen
HBHanna Brody
Hanna Brody
GLGuo-Hao Lin
Guo-Hao Lin
HRHélène Rangé
Hélène Rangé
RKRyutaro Kuraji
Ryutaro Kuraji
YKYvonne L. Kapila
Yvonne L. Kapila

1 January 2020 in Journal of Oral Microbiology
Verified
Journal Article
Open access
ARAllan Radaic
Allan Radaic
CYChangchang Ye
Changchang Ye
BPBrett Parks
Brett Parks
LGLi Gao
Li Gao
RKRyutaro Kuraji
Ryutaro Kuraji
YKYvonne L. Kapila
Yvonne L. Kapila
Oral dysbiosis is an imbalance in the oral microbiome and is associated with a variety of oral and systemic diseases, including periodontal disease, caries, and head and neck/oral cancer. Although ...

7 June 2022 in npj Biofilms and Microbiomes
Verified
Journal Article
Open access
PDF file
LGLi Gao
Li Gao
RKRyutaro Kuraji
Ryutaro Kuraji
MZMartin Jinye Zhang
Martin Jinye Zhang
AMApril Martinez
April Martinez
ARAllan Radaic
Allan Radaic
YKYvonne L. Kapila
Yvonne L. Kapila
Dysbiosis of the oral microbiome mediates chronic periodontal disease. Realignment of microbial dysbiosis towards health may prevent disease. Treatment with antibiotics and probiotics can modulate the microbial, immunological, and clinical landscape of periodontal disease with some success. Antibacterial peptides or bacteriocins, such as nisin, and a nisin-producing probiotic,Lactococcus lactis, have not been examined in this context, yet warrant examination because of their biomedical benefits in eradicating biofilms and pathogenic bacteria, modulating immune mechanisms, and their safety profile in humans. This study’s goal was to examine the potential for nisin and a nisin-producing probiotic to abrogate periodontal bone loss, the host inflammatory response, and changes in oral microbiome composition in a polymicrobial mouse model of periodontal disease. Nisin and a nisin-producingLactococcus lactisprobiotic significantly decreased the levels of several periodontal pathogens, alveolar bone loss, and the oral and systemic inflammatory host response. Surprisingly, nisin and/or the nisin-producingL. lactisprobiotic enhanced the population of fibroblasts and osteoblasts despite the polymicrobial infection. Nisin mediated human periodontal ligament cell proliferation dose-dependently by increasing the proliferation marker, Ki-67. Nisin and probiotic treatment significantly shifted the oral microbiome towards the healthy control state; health was associated withProteobacteria, whereas 3 retroviruses were associated with disease. Disease-associated microbial species were correlated with IL-6 levels. Nisin or nisin-producing probiotic’s ability to shift the oral microbiome towards health, mitigate periodontal destruction and the host immune response, and promote a novel proliferative phenotype in reparative connective tissue cells, addresses key aspects of the pathogenesis of periodontal disease and reveals a new biomedical application for nisin in treatment of periodontitis and reparative medicine.

6 October 2023 in Journal of Neuroinflammation
Verified
Journal Article
Open access
PDF file
CZChuanjiang Zhao
Chuanjiang Zhao
RKRyutaro Kuraji
Ryutaro Kuraji
CYChangchang Ye
Changchang Ye
LGLi Gao
Li Gao
ARAllan Radaic
Allan Radaic
YKYvonne L. Kapila
Yvonne L. Kapila
Introduction: Periodontitis-related oral microbial dysbiosis is thought to contribute to Alzheimer's disease (AD) neuroinflammation and brain amyloid production. Since probiotics can modulate periodontitis/oral dysbiosis, this study examined the effects of a probiotic/lantibiotic, nisin, in modulating brain pathology triggered by periodontitis.Methods: A polymicrobial mouse model of periodontal disease was used to evaluate the effects of this disease on brain microbiome dysbiosis, neuroinflammation, Alzheimer’s-related changes, and nisin’s therapeutic potential in this context.Results: 16S sequencing and real-time PCR data revealed that Nisin treatment mitigated the changes in the brain microbiome composition, diversity, and community structure, and reduced the levels of periodontal pathogen DNA in the brain induced by periodontal disease. Nisin treatment significantly decreased the mRNA expression of pro-inflammatory cytokines (Interleukin-1β/IL-1 β, Interleukin 6/IL-6, and Tumor Necrosis Factor α/TNF-α) in the brain that were elevated by periodontal infection. In addition, the concentrations of amyloid-β 42 (Aβ42), total Tau, and Tau (pS199) (445.69 ± 120.03, 1420.85 ± 331.40, 137.20 ± 36.01) were significantly higher in the infection group compared to the control group (193.01 ± 31.82, 384.27 ± 363.93, 6.09 ± 10.85), respectively. Nisin treatment markedly reduced the Aβ42 (261.80 ± 52.50), total Tau (865.37 ± 304.93), and phosphorylated Tau (82.53 ± 15.77) deposition in the brain of the infection group.Discussion: Nisin abrogation of brain microbiome dysbiosis induces beneficial effects on AD-like pathogenic changes and neuroinflammation, and thereby may serve as a potential therapeutic for periodontal–dysbiosis-related AD.

17 January 2024 in npj Biofilms and Microbiomes
Verified
Journal Article
Open access
PDF file
RKRyutaro Kuraji
Ryutaro Kuraji
CYChangchang Ye
Changchang Ye
CZChuanjiang Zhao
Chuanjiang Zhao
LGLi Gao
Li Gao
AMApril Martinez
April Martinez
YKYvonne L. Kapila
Yvonne L. Kapila
Oral microbiome dysbiosis mediates chronic periodontal disease, gut microbial dysbiosis, and mucosal barrier disfunction that leads to steatohepatitis via the enterohepatic circulation. Improving this dysbiosis towards health may improve liver disease. Treatment with antibiotics and probiotics have been used to modulate the microbial, immunological, and clinical landscape of periodontal disease with some success. The aim of the present investigation was to evaluate the potential for nisin, an antimicrobial peptide produced by Lactococcus lactis, to counteract the periodontitis-associated gut dysbiosis and to modulate the glycolipid-metabolism and inflammation in the liver. Periodontal pathogens, namely Porphyromonas gingivalis, Treponema denticola, Tannerella forsythia and Fusobacterium nucleatum, were administrated topically onto the oral cavity to establish polymicrobial periodontal disease in mice. In the context of disease, nisin treatment significantly shifted the microbiome towards a new composition, commensurate with health while preventing the harmful inflammation in the small intestine concomitant with decreased villi structural integrity, and heightened hepatic exposure to bacteria and lipid and malondialdehyde accumulation in the liver. Validation with RNA Seq analyses, confirmed the significant infection-related alteration of several genes involved in mitochondrial dysregulation, oxidative phosphorylation, and metal/iron binding and their restitution following nisin treatment. In support of these in vivo findings indicating that periodontopathogens induce gastrointestinal and liver distant organ lesions, human autopsy specimens demonstrated a correlation between tooth loss and severity of liver disease. Nisin’s ability to shift the gut and liver microbiome towards a new state commensurate with health while mitigating enteritis, represents a novel approach to treating NAFLD-steatohepatitis-associated periodontal disease.